Here’s What U.S. Health Experts Learned from Ebola One Year Later

What did the U.S.’s top health leaders learn from the Ebola outbreak, and how prepared is our health system for another case of Ebola or another infectious disease? HHS Secretary Burwell, CDC Director Tom Frieden, NIAID Director Tony Fauci, and HHS Assistant Secretary for Preparedness and Response Nicole Lurie talk about lessons learned and the path forward. Learn More >>

HHS advances development of new monoclonal antibody drug for Ebola

Novel technology holds potential for public health responses

A novel Ebola virus disease treatment based on three monoclonal antibodies will advance in development through an agreement between ASPR and Regeneron Pharmaceuticals. By rapidly developing new drugs to treat Ebola, ASPR hopes to bring future outbreaks under control more quickly. Learn more >>

HHS explores new disaster use of approved ‘clot busting’ drug

Drug shows promise as potential lifesaver in mustard gas attack

Could a clot-busting drug that is currently being used to treat strokes and heart attacks also save lives in the event of a mustard gas attack? HHS has awarded a contract to find out if an existing drug can be used in new ways to save more lives.Learn More >>

National Health Security: An Introduction

As disasters and emergencies become more common and costly, advancing our nation's preparedness is even more important. That's where national health security comes into play. National health security is creating healthy and safe conditions where we live, work, and play. By introducing national health security into our everyday approach to life, we strengthen our communities, protect our health, and decrease the time it takes to recover from disasters. Find out what you can do to enhance national health security. Learn More >>

From the ASPR Blog: Innovative Partnerships Support Antibiotic Development

Can a federal agency engage in long-term strategic partnerships with business? Yes. BARDA is pioneering an innovative approach to collaboration that uses Other Transaction Authority(OTA) to create flexible business partnerships between government and industry. Partnerships formed under OTA allow both parties to invest in the development of a portfolio of products for biodefense and to combat the growing public health threat of antibiotic resistance. Learn More >>